This NDC is on FDA's drug shortage list (posted Feb 20, 2018)
Reported reason: Demand increase for the drug
Product Information
LIDOCAINE HCL 1% 20 MG/2 ML VL is a generic product labeled by Eugia US LLC, priced at $0.8379 per ML under NDC 55150016102. Its NADAC has been published 224 times since May 18, 2022.
FDA first approved this application on Mar 14, 2013. Its Orange Book therapeutic-equivalence code is AP.
Strength
10 mg/mL
Manufacturer
Eugia US LLCNDC
55150016102
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
EPIDURAL; INFILTRATION; INTRACAUDAL; PERINEURAL
Effective Date
9/23/2026
Active Ingredients
LIDOCAINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA203082FDA Approved
3/14/2013
TE Code
AP
On Market Since
3/14/2013
Pharmacological Classes
Price Statistics
The NADAC for LIDOCAINE HCL 1% 20 MG/2 ML VL has been published 224 times since May 18, 2022, and over the history we have for it it has risen 11.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8379 per ML |
|---|---|
| All-time high | $0.8756 (Aug 12, 2026) |
| All-time low | $0.7533 (May 18, 2022) |
| 52-week high | $0.8756 |
| 52-week low | $0.7557 |
| Median price | $0.8036 |
| Average price | $0.8094 |
| Largest weekly change | +14.3% (Jun 21, 2023) |
| Weeks tracked | 224 |
| Tracking since | May 18, 2022 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 92% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eugia US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lidocaine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Amide Local Anesthetic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LIDOCAINE HCL 1% 20 MG/2 ML VL?
The current National Average Drug Acquisition Cost (NADAC) for LIDOCAINE HCL 1% 20 MG/2 ML VL, manufactured by Eugia US LLC, is $0.8379 per ML (NDC 55150016102), effective Sep 30, 2026.
How has the price of LIDOCAINE HCL 1% 20 MG/2 ML VL changed over time?
Over the history we have for it, the NADAC for LIDOCAINE HCL 1% 20 MG/2 ML VL has risen 11.2%. It has been tracked across 224 weekly CMS publications since May 18, 2022.
What are the highest and lowest recorded NADAC prices for LIDOCAINE HCL 1% 20 MG/2 ML VL?
Since May 18, 2022, the NADAC for LIDOCAINE HCL 1% 20 MG/2 ML VL has ranged from a low of $0.7533 (May 18, 2022) to a high of $0.8756 (Aug 12, 2026), with a median of $0.8036 per ML.
Are there cheaper alternatives to LIDOCAINE HCL 1% 20 MG/2 ML VL?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LIDOCAINE HCL 1% 300 MG/30 ML, is $0.0681 per ML — about 92% below LIDOCAINE HCL 1% 20 MG/2 ML VL.
Who manufactures LIDOCAINE HCL 1% 20 MG/2 ML VL?
LIDOCAINE HCL 1% 20 MG/2 ML VL (NDC 55150016102) is labeled by Eugia US LLC, and CMS classifies it as a generic product.
Is LIDOCAINE HCL 1% 20 MG/2 ML VL in shortage?
Yes — NDC 55150016102 is currently listed in FDA's drug shortage database (posted Feb 20, 2018). Reported reason: Demand increase for the drug.